News

HPV vaccine rates perpetuate racial and geographic cancer disparities


 

FROM AN AACR MEETING

References

SAN ANTONIO – Girls who live in states with higher rates of cervical cancer incidence and mortality are less likely to receive the human papilloma virus vaccine, researchers reported at a meeting on disparities in cancer health care held by the American Association for Cancer Research.

Additionally, girls living in states with a higher proportion of black residents and a lower proportion of high-income residents were less likely to receive the full three-dose course of human papilloma virus (HPV) vaccine. Immunization with the HPV vaccine can help prevent several types of cancers including cervical, anal, vaginal, and vulvar cancers. The researchers analyzed state data primarily from 2012 on vaccination rates, cancer rates, demographics, and use of healthcare.

Girls in states with higher rates of cervical cancer incidence and mortality are less likely to receive the HPV vaccine. ©Micah Young/istockphoto.com

Girls in states with higher rates of cervical cancer incidence and mortality are less likely to receive the HPV vaccine.

A health care provider’s recommendation was the biggest influence on whether a teen received the vaccine, said Jennifer L. Moss, a doctoral student at the University of North Carolina Gillings School of Global Public Health, who led the research. Ms. Moss said the research team hopes the findings will encourage clinicians in states with higher rates of cancer linked to HPV to recommend vaccination to adolescents at every visit.

Teens who have more contact with the health care system are also more likely to receive the full three doses of vaccine, the researchers found. As a result, the researchers also suggest improving access to preventive health care for adolescents in states with higher rates of HPV-related cancers.

Recommended Reading

CAR T cells can produce durable remissions
MDedge Hematology and Oncology
RNAi therapy may eliminate resistance in B-ALL
MDedge Hematology and Oncology
Air pollution not to blame for childhood leukemia, study suggests
MDedge Hematology and Oncology
Enzyme ‘switch’ is key to new treatment strategy for T-ALL
MDedge Hematology and Oncology
CAR T cells serve as bridge to HSCT in ALL
MDedge Hematology and Oncology
A safer gene therapy for SCID-X1?
MDedge Hematology and Oncology
Risk-directed therapy improves survival in ALL
MDedge Hematology and Oncology
Preventing cancer-related infection
MDedge Hematology and Oncology
Proper transfusion practice prevents CMV
MDedge Hematology and Oncology
Cancer treatment during pregnancy can be safe
MDedge Hematology and Oncology